2nd CRISPR-Based Therapy Analytical Development Summit
The 2nd CRISPR-Based Therapy Analytical Development Summit is returning to Boston this September to unite 50+ key figures across Analytical Development, CMC & QC domains, all with the common goal of developing more precise, accurate, and sensitive analytical assays.
Download the 2024 event guide to learn more.
Join us to explore the latest analytical innovation across both traditional and disruptive CRISPR-based therapies, and in vivo and ex vivo delivery, with expert discussions covering core themes such as:
- Characterization of guides, nucleases, delivery methods, and full drug constructs, with Editas Medicine, Beam Therapeutics & Nvelop Therapeutics
- Robust non-clinical and CMC assay development, including biodistribution studies, potency assays, and on-/off- target sequencing detection, nomination, and prediction, with Tome Biosciences, Verve Therapeutics & Vertex Pharmaceuticals
- Meeting regulatory expectations for analytical data to successfully support IND submissions, with NIST, Prime Medicine & Metagenomi
Are you working to develop, characterize, and validate more robust analytical tools to enable the progression of your early R&D work into a clinical therapy? Then this is the leading collaborative forum to equip you with the latest innovation, case studies, and actionable insights to boost your analytical panel and strategy.
Register your place on the official event website today.
Dates: September 17-19, 2024
Location: Hilton Boston Logan Airport, One Hotel Drive, MA 02128, United States
